Healthcare / Medical DevicesLSE
$14.06
+0.11 (+0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-23.2M · quality 67.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$63M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-67.7%
↓Gross Margin
47.5%
↓Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-45.8%
FCF CAGR
—
FCF margin
-565.0%
FCF / Net income
0.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.0M · net income $-28.7M · FCF $-22.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.0M | $4.0M | $4.0M | $27.2M | $25.2M |
| Net Income | $-28.7M | $-28.7M | $-21.7M | $-26.9M | $-24.6M |
| EBITDA | $-26.1M | $-26.1M | $-22.8M | $-27.5M | $-27.4M |
| EPS | -0.08 | -0.08 | -0.07 | -0.14 | -0.14 |
| Gross Margin | 47.5% | 47.5% | 57.5% | 48.5% | 46.0% |
| Operating Margin | -720.0% | -720.0% | -672.5% | -112.9% | -118.9% |
| Net Margin | -717.5% | -717.5% | -542.5% | -98.9% | -97.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.14 | 0.24 | 0.14 |
| Current Ratio | 4.65 | 4.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-22.6M | $-22.6M | $-23.2M | $-28.2M | $-32.1M |
| Returns | |||||
| ROE | -67.7% | -67.7% | -36.3% | -54.6% | -33.5% |
| Valuation | |||||
| P/B | 122.73 | 122.73 | 230.30 | 90.12 | 321.83 |
| Growth & Yield | |||||
| Revenue Growth | 0.0% | 0.0% | -85.3% | 8.1% | — |
| EPS Growth | -14.3% | -14.3% | 51.6% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.07 → -0.08
Residual
-12.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.